Danaher Corporation, a life sciences and diagnostics company focused on advancing human health, has announced that Matthew Gugino will become Chief Financial Officer, effective February 28, 2026. Gugino currently serves as Group CFO of the Life Sciences Innovations Group and Vice President of Financial Planning & Analysis. He will succeed Matthew McGrew, who has held the CFO position since 2019 and will continue as Executive Vice President during a gradual transition to retirement. “Matt McGrew’s financial leadership over the past two decades has been instrumental in shaping the Danaher you see today. He played a pivotal role in the acquisition of Cytiva, the launches of Envista and Veralto as public companies, and navigating through the pandemic—all while developing a deep talent bench,” said Rainer Blair, President and CEO. Blair credited McGrew with leading key initiatives such as the acquisition of Cytiva and the launches of Envista and Veralto.
Blair also expressed confidence in Gugino’s appointment, noting, “His broad experience across Investor Relations, FP&A, M&A, talent development, and most recently as Group CFO, makes him exceptionally well prepared for this next chapter.” Gugino joined Danaher in 2013 after working in equity research and public accounting. McGrew’s tenure saw Danaher nearly double its revenue and market capitalization, while improving growth and margins. Gugino’s promotion is expected to support Danaher’s continued focus on scientific advancement and operational excellence as it navigates its next phase of growth.
